Cargando…
Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19
Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda. https://bit.ly/3iaNBsB
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340617/ https://www.ncbi.nlm.nih.gov/pubmed/34326192 http://dx.doi.org/10.1183/13993003.02002-2021 |
| _version_ | 1783733806698594304 |
|---|---|
| author | Xu, Jiuyang Cao, Bin |
| author_facet | Xu, Jiuyang Cao, Bin |
| author_sort | Xu, Jiuyang |
| collection | PubMed |
| description | Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda. https://bit.ly/3iaNBsB |
| format | Online Article Text |
| id | pubmed-8340617 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83406172021-08-09 Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 Xu, Jiuyang Cao, Bin Eur Respir J Editorials Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda. https://bit.ly/3iaNBsB European Respiratory Society 2022-01-06 /pmc/articles/PMC8340617/ /pubmed/34326192 http://dx.doi.org/10.1183/13993003.02002-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
| spellingShingle | Editorials Xu, Jiuyang Cao, Bin Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title | Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title_full | Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title_fullStr | Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title_full_unstemmed | Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title_short | Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19 |
| title_sort | lessons learnt from hydroxychloroquine/azithromycin in treatment of covid-19 |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340617/ https://www.ncbi.nlm.nih.gov/pubmed/34326192 http://dx.doi.org/10.1183/13993003.02002-2021 |
| work_keys_str_mv | AT xujiuyang lessonslearntfromhydroxychloroquineazithromycinintreatmentofcovid19 AT caobin lessonslearntfromhydroxychloroquineazithromycinintreatmentofcovid19 |